clinical genomics

Called GA4GH Connect, it calls on the alliance's 500-plus members to develop new data sharing standards for use in major international genomic data initiatives.

The researchers are developing a province-wide registry of targeted sequencing test results for the study that will be made available to other cancer researchers.

Using data from the Parkinson's Progression Markers Initiative, GNS Healthcare identifies genetic and molecular markers of rapid motor progression.

Spun out of Moffitt Cancer Center, M2Gen and the Total Cancer Care protocols promise rapid advancements in precision medicine, starting with oncology.

Israeli genomic analysis startup Genoox hopes to lower the barrier to entry for next-generation sequencing, making it accessible to non-academic centers.

Publishing house Hearst is pushing into precision medicine with a $75 million investment in M2Gen, the informatics subsidiary of Moffitt Cancer Center.

Despite years of experience of returning genetic test results, clinicians and researchers are still faced with many questions, such as what to do about VUS and secondary findings.

The consortium aims to advance the use of genomics in the clinic, with a particular  focus on diverse and underserved patient populations.

The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.

The funding will support groups participating in the Implementing Genomics in Practice II: Pragmatic Clinical Trials Network initiative.

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.